TARA Biosystems, a biotech startup that’s built a mechanism to generate human tissues outside of the body for drug development testing for cardiovascular therapeutics, has been acquired by Valo Health, a drug discovery and development platform that leverages AI-powered computation and data. “TARA’s proprietary human cardiac disease platform enables Valo to advance the discovery of new medicines for cardiovascular disease, ushering in a new era for patients,” remarked Misti Ushio, Founder and CEO of TARA. “TARA joining the Valo family is a natural extension of our pre-existing business relationship and is a unique fit given our shared vision of leveraging machine learning and human-centric data to transform the treatment of cardiovascular diseases.”
TARA’s proprietary human cardiac disease platform enables Valo to advance the discovery of new medicines for cardiovascular disease, ushering in a new era for patients. TARA joining the Valo family is a natural extension of our pre-existing business relationship and is a unique fit given our shared vision of leveraging machine learning and human-centric data to transform the treatment of cardiovascular diseases. – Misti Ushio
Founded by Boyang Zhang, Gordana Vunjak-Novakovic, Kacey Ronaldson, Milica Radisic, and Yimu Zhao in 2014, TARA Biosystems had raised a total of $21.3M in reported equity funding with the company’s last round in 2020. Backers include 180 Degree Capital, Partnership Fund for New York City, Lifeforce Capital, Alexandria Venture, DEFTA Partners, New York Ventures, Tachyon Ventures, OMX Ventures, Morgan Noble, and Trancos Ventures.
“This acquisition builds on Valo’s unyielding commitment to identify new treatments for cardiovascular disease, creating a best-in-class end-to-end drug discovery and development platform aimed at accelerating the delivery of lifesaving drugs to the millions of patients suffering from cardiovascular diseases,” remarked David Berry, Founder and CEO of Valo.
This acquisition builds on Valo’s unyielding commitment to identify new treatments for cardiovascular disease, creating a best-in-class end-to-end drug discovery and development platform aimed at accelerating the delivery of lifesaving drugs to the millions of patients suffering from cardiovascular diseases -David Berry
